The term liquid biopsy comprises methods of blood-based analysis of nucleic acids, which are increasingly under discussion in oncology and personalized medicine, and are already applied in individual cases. The analysis of tumor markers, which in certain tumor diseases can be found as protein markers in vast amounts in the blood, constitutes a primary form of liquid biopsy. Cell-free circulating DNA fragments in the blood (ctDNA), which reflect the genetic profile of a tumor cell and are released in different ways by the tumor, represent a new class of more specific and sensitive biomarkers that can be correlated with the dynamics of the tumor disease. New technologies based on PCR and sequencing techniques pave the way for diagnostic approaches to define molecular tumor characteristics, not only in tumor tissue but also in the blood, by analyzing cell-free circulating DNA.
Introduction
The earliest report of cell-free DNA in healthy individuals dates from 1948. Mandel and Metais described the presence of cell-free deoxyribonucleic acid (cfDNA) in human blood [1] . However, until recently the most common clinical use was the evaluation of fetal DNA in the circulation of pregnant women. Investigation of cell-free fetal DNA (cffDNA) can now uncover germline fetal changes just weeks after conception. The detection of aneuploidy has become part of the standard prenatal assessment in high risk women [2, 3] . Other studies have shown that cfDNA exists at a ready-state level in clinical scenarios such as myocardial infarction, surgery, trauma and stroke. Cellfree DNA may increase dramatically with cellular injury or necrosis [4] [5] [6] [7] .
In oncology, there are a variety of potential clinical applications for non-invasive disease monitoring based on tumor specific genetic alterations detectable in circulating cell-free tumor DNA (ctDNA). The importance of ctDNA was recognized in 1994 as a result of the detection of mutated RAS genes in patients with malignant hematological disease [8] . Microsatellite alterations were shown in cfDNA in head and neck cancer patients [9] . Investigation of ctDNA in cancer patients has recently increased, largely based on the advances in genomic technologies with increasing sensitivity and specificity to detect mutant variants at a very low allelic level in complex mixtures of DNA. Deep sequencing technologies, cold-PCR, droplet-digital PCR and BEAMing (beads emulsion amplification and magnetics) were used and reported to serve as feasible methods to detect tumor specific genetic alterations in ctDNA from plasma samples. Liquid biopsy has become one of the most exciting and controversial research fields in precision medicine.
Defining circulating cell free DNA and approaches to liquid biopsy analysis
There is an enormous research effort focused on understanding the utility of free circulating nucleic acids (DNA, mRNA and microRNA miRNA) in pathological processes including malignant and benign tumor diseases as well as inflammatory processes, stroke, trauma and sepsis [1, 8, 10] . Active, as well as passive processes are responsible for the release of DNA into the peripheral blood. During these processes nucleic acids are shed into the blood by apoptotic and necrotic cells. The concentration of tumor derived DNA is dependent on the turnover of tumor cells and may be different from one tumor entity to the other. CtDNA is a tiny proportion of the cell free DNA from tumor cells and may be different from one tumor entity to the other [11] . It is important to note that ctDNA is distinct from circulating tumor cells which specifically refers to intact cells [12] . However, circulating tumor cells in blood are known to contribute to the release of ctDNA. Cell-free DNA (cfDNA) is also released by dying nonmalignant host cells, and this normal cfDNA dilutes the ctDNA in patients with cancer.
Depending on the extent of tumor disease and in particularly on the histological tumor type, the fraction of ctDNA varies greatly, between 0.01% and more than 90% [13] . It has been estimated that a tumor of 100 g in weight corresponds to 3 × 10 10 tumor cells and up to 3.3% may enter the blood every day [14] . The average size of ctDNA is 70-200 base pairs. During tumor development and tumor progression both tumor derived and normal wild-type cell free DNA will be released into the blood. The proportion of ctDNA originating from the tumor cells varies depending on the tumor stage and size, but may also be influenced by the tumor environment; in particular in situations when tissue-damaging therapies such as surgery, chemotherapy, or radiotherapy have been applied [12] . The DNA fragment length might provide some information on the origin of cfDNA [15, 16] . Although the clearance of cfDNA is not fully understood it is known that cfDNA has a short half-life time of 15-20 min [17] and is cleared through the liver and kidneys [18] .
It is known that cancer patients have higher cfDNA levels than healthy donors, however, the overall concentration of cfDNA varies considerably in blood samples in both groups [19] [20] [21] [22] [23] . An average of 180 ng cfDNA per mL of blood has been measured in cancer patients, whereas healthy individuals carry about 30 ng of cfDNA per mL of blood [24] . A prospective study of cell-free DNA levels in plasma samples and their impact in cancer patients showed considerable variation between the European Prospective Investigation into Cancer and Nutrition (EPIC) centers [23] . It was discussed that this individual variation ( Figure 1 ) was due to the type of population and the treatment of samples. Thus, the cfDNA concentrations alone are not the only tool in a diagnostic setup including liquid biopsies, and may not be predictive for the amount of ctDNA ( Figure 1 ). The impact of the different mechanisms involved in generating cell-free DNA and the release into the circulation needs further investigation, but will be crucial to validate cfDNA as a biomarker.
However, an ever-growing number of reports convincingly show the suitability of ctDNA to detect tumorspecific genetic alterations. Cell-free DNA includes coding and non-coding genomic DNA. Tumor-specific gene mutations such as point mutations, deletions, insertions, amplifications, translocations and methylation abnormalities may be present in ctDNA and, depending on the technical approach, detectable in liquid biopsies.
Methods in ctDNA analysis
Both normal cells as well as tumor cells steadily release DNA fragments, which are present in the cell-free fraction of the blood. In most cases ctDNA is only a tiny fraction of the complete cfDNA. Because of ongoing lysis of the normal cells in the blood, the already tiny amount of ctDNA is even more diluted by cfDNA complicating the detection of biomarkers from the tumor. Therefore, a delay in processing the collected blood, agitation of the sample, as well as sample transport cause the additional release of wild-type cfDNA from lyzed blood cells, and thereby influence the ratio between ct and cfDNA [25] . To reduce continuous "contamination" of the specimen and to facilitate comparisons of results from different laboratories, pre-analytical procedures have to be standardized seriously in future.
Two main applications can be distinguished with respect to the analysis of ctDNA. The first application is a targeted approach based either on the analysis of known genetic changes identified in the primary tumor together with a follow-up of the patient, or used as a screening technique alongside the early identification of resistance against therapeutic drugs. Many mutations causing resistance are known and therefore patients can be tested for these variations.
The second application is a genome wide approach without the prior knowledge of specific changes in the primary tumor. Whilst the targeted approach, due to its high sensitivity, also allows analysis of minor tumor fractions, the genome wide application is limited to high tumor fractions (>10%) [26] . However, this genome wide screening approach will be the final goal and will help to identify patients before they fall ill.
Besides next-generation sequencing (NGS), mutation specific real-time or end-point PCR methods are applied for the targeted analysis of point mutations, deletions and genomic rearrangements.
Due to the extremely high sequencing capacity, NGS enables a high diagnostic sensitivity even for the parallel sequencing of entire gene panels. In addition parallel handling of samples is simple and can easily be automated, making the processing more cost-effective.
However, the sensitivity of amplicon-based NGS is limited by the error rate of the DNA polymerase used, which is generally 0.01% [27] .
On the other hand, techniques like Sanger sequencing or pyrosequencing can only be used for patients that exhibit a high amount of ctDNA and therefore are not really applicable for the analysis of liquid biopsies. 
Deep sequencing-based approaches/ NGS-based methods
The NGS-based methods sensitivity depends primarily on the sequencing depth. With 1000x vertical coverage of the target region-this depth can easily be obtained -the sensitivity is approximately 1%-5% mutation load in the wild-type background. Despite enormous recent efforts, NGS-based methods frequently fail to detect biomarkers in liquid biopsies of stage 1 patients purely because of lack of sensitivity and the small amount of ctDNA present in the blood of these patients.
However, because of the enormous interest in the early detection of meaningful biomarkers numerous techniques have been developed to reduce the detection limit. These technical developments are rapidly improving sensitivity, although even the most sophisticated techniques are far from satisfactory for the routine detection of biomarkers e.g. in stage 1 patients.
The most promising technique at the moment was recently published by Newman et al. [28] , a capture-based NGS ctDNA detection method called CAncer Personalized Profiling by deep Sequencing (CAPP-Seq) designed especially for detection of all known major classes of mutations in non-small cell lung cancer (NSCLC). Capture-based NGS methods enrich for genomic regions before sequencing and the capture library (a custom-derived collection of targetspecific oligonucleotides) can easily be adapted for any given cancer type. According to the authors, their CAPP Seq approach identified mutations in >95% of tumors with high specificity and sensitivity down to approximately 0.02% [28, 29] . However, although ctDNA was detected in the majority of patients with stage II-IV disease, biomarkers could be identified in only 50% of patients with early-stage NSCLC (stage I). The same authors recently re-engineered their approach by combining a digital error suppression (iDES) technique to reduce background artifacts with a molecular barcoding strategy for the efficient recovery of cfDNA molecules. This combination of techniques resulted in a 15-fold improvement in respect to sensitivity [30] . This example shows that detection of unknown biomarkers within a screening procedure in stage 1 tumor patients is currently at the technical limits of known methods, and that only a combination of bioinformatics and sophisticated molecular techniques will solve this problem.
A further option is the Safe-SeqS (Safe-Sequencing System). The Safe-SeqS adds a unique identifier (UID) to every DNA template molecule. After amplification of the templates a lot of clonal amplicons of the original molecule are formed. If a mutation is present in the original molecule, it should turn up in all the other molecules with the same identifier. If a mutation is found in a UID family with >95% the mutation is considered to be real. A lower percentage indicates a technical artifact. Besides technical know-how; this method requires extensive bioinformatic knowledge [31] .
With further improvements in sensitivity, NGS technologies will become increasingly important in future clinical applications, so that even genome wide analyses with low tumor fractions will be possible and cost effective.
Quantitative PCR-based methods
Most relevant at the moment is the specific detection of a set of mutations known to be important and useful for assessment of the patients' disease. For this purpose a couple of sensitive PCR based techniques have been developed, and constantly improved in recent years.
In most cases real-time PCR, or techniques based on it, are used for targeted mutation detection. Thereby the relevant mutation is quantified via fluorescently labeled probes. Standard curves with known concentrations are used to calculate the concentration of the target sequence. Ideally a couple of housekeeping genes are used for normalization because PCR performance depends on the amplification efficacy of the assays and sample quality. Real-time PCR is a very fast method for the targeted detection of mutations with a sensitivity of approximately 0.1% mutation load in a wild-type background. The sensitivity of real-time PCR can also be increased e.g. by additional nested PCR methods, allele-specific PCR or by suppressing the wild-type allele. This technology generally allows a report turnaround time of 1 day.
Digital PCR (dPCR) was recently introduced as a further improvement to real-time PCR. dPCR allows quantification of identified mutations in a simple, sensitive and cost effective way. In contrast to real-time PCR, no standard curves, references or calibrators are needed for the normalization of the data. The DNA-molecules in the probe are diluted and partitioned into hundreds or even millions of separate reaction chambers so that each contains one or zero copies of the sequence of interest. As with real-time PCR, the fluorescent signals indicating positive reactions to a specific mutation are set in ratio to the positive reactions of the corresponding wild-type sequence. By counting the number of"positive" partitions (in which the sequence is detected) after PCR versus "negative" partitions (in which it is not), you can determine exactly how many copies of a DNA molecule were in the original sample. Positive reactions are labeled as "1" and negative reactions as "0", hence the term " digital" PCR [32] . By using dPCR it is possible to reach a sensitivity of >0.01% mutation load in a wild-type background. However, this high sensitivity increases the risk of falsepositive signals and values. Thus, the applied assays must be checked thoroughly beforehand for their false-positive rates. This technology generally allows a report turnaround time of 1 day.
Different platforms are used for dPCR. They can be distinguished according to the applied methods. Droplet-based digital PCR platforms utilize water-in-oil emulsions for the PCR reactions. Chip-based systems utilize micro-reaction chambers on their surfaces for the clonal amplification.
Clinical application of ctDNA diagnostics
The feasibility of "liquid biopsy" analyzing ctDNA for early detection of cancer, real-time monitoring and therapeutic stratification of cancer patients is presented and extensively discussed in a growing number of studies.
Screening and early detection of cancer by analyzing ctDNA may be of particular interest in patients with a high risk of developing cancer [33, 34] . The greatest technical challenge is the identification of very low amounts of ctDNA within a background of cfDNA. Besides the necessary sensitivity, the choice of the cancer-specific gene panel is essential to reveal reliable results. In one study of 640 cancer patients, ctDNA alterations were identified in 48%-73% of patients with localized cancer diseases (colorectal, gastroesophageal, pancreatic and breast cancer) [11] . These detection rates are not considered satisfactory for the early detection of cancer. Further large studies are required comparing patients with particular cancer types to healthy individuals to define sensitivity and specificity, and finally to define an appropriate panel of genetic alterations most likely associated with early cancer diseases. However, cancer associated mutations can occur with increasing age even in persons who never develop cancer [35] . Thus, the detection of ctDNA carrying cancer associated mutations has to be interpreted critically and does not yet prove an early cancer diagnosis.
In contrast, real-time tumor monitoring and molecular stratification has become an important object in the treatment of cancer patients. The blood-based stratification of targeted therapy may become one way to include liquid biopsy into clinical routine diagnostics.
Although circulating biomarkers such as protein biomarkers prostate cancer antigen (PSA), CA-19-9 and CA-125 (carcinoembryonic antigen) are widely used in assessing therapeutic response, they lack specificity and may also be elevated by circumstances unrelated to the disease [17, [36] [37] [38] [39] ; molecular biomarkers facilitate tumor genotyping thus helping to categorize tumors for clinical decisions. Thus, patients likely respond to various drugs can be identified and therapies could be applied which are tailored to the genetic composition of the tumor.
There is no question that the earlier biomarkers can be detected the better it is for the treatment of the patient. Nowadays most biomarkers are DNA based and consequentially the detection of tumor-specific genetic alterations in ctDNA leads to broad clinical applications to evaluate diagnosis and prognosis, and in particular to identify predictive biomarkers in blood.
However, tumor tissue is the gold standard for investigational and clinical molecular pathology allowing the verification of biomarkers, of which almost all are "driver mutations" representing "druggable" kinase alterations. These kinases widely represent the basis for targeted therapies. Agents such as trastuzumab, imatinib, cetuximab, gefitinib and vemurafenib are kinase inhibitors used in treatment of cancer patients with colorectal and lung cancer and those suffering from melanoma and gastrointestinal stromal tumors. Since histopathological examination is the first step in tumor diagnosis, tumor tissue material is usually available. Although routine biopsy tumor samples are usually formalin-fixed and paraffin embedded (FFPE) they are suitable for cancer genome diagnostics. By applying gene panel testing, a growing number of therapeutic relevant biomarkers can be detected in the primary tumor material. Treatment relevant biomarkers such as EGFR alterations in lung cancer and KRAS, NRAS and BRAF mutations in colorectal cancer have to be known to be used for treatment decisions and can additionally be applied as molecular biomarkers in tumor monitoring.
Several studies have shown that liquid biopsies may be useful to monitor tumor burden [27, [40] [41] [42] [43] . There is convincing evidence to include oncogenic molecular biomarkers based on ctDNA analysis during cancer patient monitoring. In a study of patients with various cancer types it was shown that about 80% of patients with advanced disease had detectable ctDNA in blood [11] . In patients with localized disease up to 75% those with colorectal cancer patients had KRAS mutant DNA fragments in their plasma corresponding to the KRAS mutation in the primary tumor. It has also been shown that high ctDNA levels were associated with decreased 2-year survival [11] .
Advances in molecular technology have improved the analysis of even small amounts of tumor material to detect cancer gene panels. If specific mutations are defined by evaluation of the primary tumor, these may be used for ctDNA analysis. In the future, cancer patients will increasingly have their tumors genetically analyzed to guide treatment decisions. Thus, more genetic information will be available from the primary tumor and may be utilized for ctDNA analysis in tumor monitoring ( Table 1) .
The use of molecular targeted therapies has advanced and has been shown to be successful by extended disease free survival, in particular in colorectal and lung cancer. However, the greatest challenge of these treatment strategies is therapy resistance due to "new" mutations developing under exposure to monoclonal antibodies and tyrosine kinases (TKIs). For colorectal cancer, NSCLC resistance mutations are well known and can be identified within 12-14 months of starting treatment. Also in colorectal cancer, mutations in KRAS codon 12/13 and 61 as well as BRAF were known to be associated with therapy resistance to cetuximab or panitumumab. These genetic alterations may occur under therapy even in patients with wild-type RAS status in the primary tumor [44] [45] [46] [47] . Similar treatment failure is known for patients with NSCLC. Cellular mechanisms of de novo and acquired resistance to EGFR TKI therapy in NSCLC include various molecular abnormalities in tumor cells such as constitutive activation of transducers located downstream of EGFR, overexpression of other tyrosine kinase receptors, or in particular secondary EGFR mutations. Among patients exhibiting acquired resistance, a secondary EGFR exon 20 mutation (T790M) occurs in about 50% of cases and an amplification of MET has been detected in up to 20% of EGFR TKI-resistant tumors [48] [49] [50] [51] [52] [53] [54] [55] . Minor clones with the T790M mutation have been identified in Table 1 : Currently utilized predictive molecular biomarkers, which may also be used for tumor monitoring in liquid biopsies.
Tumor type Gene
Colorectal Cancer
treatment-naive NSCLCs that contain classic sensitizing EGFR mutations. Treatment pressure may select growth enrichment of these minor T790M cell clones leading to treatment failure [56] . The most likely reason this mutation in primary tumors may be missed is due to the low sensitivity of detection methods such as Sanger sequencing. Choosing higher sensitivity methods may reveal more primary lung tumors carrying the resistance mutation in addition to the classic sensitizing EGFR mutation. Recent studies have shown that alternate methods reveal T790M mutations in up to 79% of EGFR-mutant primary NSCLC tumors [54, 55, 57, 58] . Although, applying more sensitive detection methods such as NGS, dPCR or Beaming technology will provide more insight into the molecular mechanisms of tumor development and tumor progression, heterogeneity is one reason treatment relevant mutations such as T790M are missed at initial diagnosis. It is still unclear, and under discussion, as to whether the analysis of ctDNA in liquid biopsies is suitable to characterize the mutation status of a tumor in general. The total concentration of ctDNA in the blood of cancer patients varies, and the presence of tumor-specific mutations corresponding to minor tumor cell clones may be undetectable initially. However, during tumor progression a growing clone with rare, and in particular, resistance mutations can be identified in liquid biopsies analyzing ctDNA. Improvements in analytical sensitivity and specificity allow tracking of resistance mutations in tumor patient management. Recently, the first ctDNA based test utilizing liquid biopsies in EGFR gene testing was approved [59] . The use of a TKI (IRESSA ® ) is permitted for EGFR mutation analysis of ctDNA in liquids. Furthermore, a third generation TKI (Tagrisso ® ) has been licensed for patients carrying the T790M mutation. Liquid biopsies are particularly recommended for testing for T790M status due to the fact that tumor tissue may not be available in progression.
In a case of our own, a patient with a NSCLC carried a common EGFR mutation in exon 19. He developed resistance to first generation TKIs and relapsed. Re-biopsy at progression was not available thus a liquid biopsy was analyzed for T790M. As shown in Figure 2 , both mutations in T790M in exon 20, and in exon 19 of the EGFR gene were detectable in the plasma fraction.
Although tumor tissue may still be the gold standard for the detection of "druggable" targets, cancer liquid biopsy is a promising tool in tumor monitoring. A proposed workflow to analyze tumor tissue and plasma samples within a comprehensive diagnostic procedure is given in Figure 3 . Using the mutation profile detected in the primary tumor material as a "leading biomarker" the interpretation of results from liquid biopsies may be easier, in particular when negative results for the resistance mutations are obtained. The detection of a biomarker previously known from the primary tumor analysis, in a plasma sample during tumor monitoring indicates usability of the plasma sample and the obtained result. It may also be useful to monitor tumor burden which is a central aspect in cancer patient management that is typically assessed with imaging. Tumor progression is a dynamic process triggered by the molecular heterogeneity of the tumor cells. In analyzing tumor tissue obtained from biopsies the genetic heterogeneity may be missed due to the limited material and the low number of tumor cells. It is well known that different areas of the same tumor show different genetic profiles [60, 61] . One further promising advantage of utilizing liquid biopsy as a diagnostic tool in cancer treatment procedures is the detection of a mutational profile consisting of prognostic and predictive biomarkers in tumor monitoring which may be undetectable in primary tumor tissue.
Conclusions
Primary tumor diagnosis is based on histological examination and tumor typing using morphological and molecular characteristics. However, current treatment strategies in cancer patients are more and more determined by targeted drugs based on the individual molecular biology of a tumor disease. Thus, molecular profiling of tumor material is an important task and a still growing field in tumor pathology. Tumor tissue acquisition becomes an increasingly challenging due to minimal invasive procedures with limited tumor material. For the primary diagnosis of tumors or metastases that are not easy to biopsy but need to be analyzed for molecular targets, liquid biopsy might be an alternative. This has been shown by promising results in lung cancer patients regarding the detection of resistance mutations such as T790M. However, although highly sensitive and specific methods are used to detect ctDNA it should be emphasized that sensitivity is still a limitation. CtDNA concentrations may vary due to reasons such as pre-analytical procedures and ctDNA release. Interpretation of genetic alterations detected exclusively in liquid biopsy may prove difficult. A known molecular profile of the primary tumor may be helpful in the interpretation of molecular data from liquids. This tissue related data provides useful information regarding the specificity in particular when using gene panels. Despite the promising first results of liquid biopsy diagnostics there is a limited impact in clinical diagnostics. Detecting and tracking resistance mutations in lung cancer is one approach but if possible biopsy material or fluids (e.g. pleura) should be analyzed, in particular when ctDNA results from liquids do not show any mutations. The clinical utility of liquid biopsy based on ctDNA analysis has to be addressed in future clinical trials.
The early detection of cancer faces challenges of both sensitivity and specificity and reliable testing based on ctDNA is still far away. The proposition of companies and public press "cancer detection from a drop of blood" is still a vision for the future and distant from realty.
In summary, the gold standard of tumor diagnosis is based on morphological and molecular examinations from tumor tissue material but liquid biopsies are increasingly becoming an auspicious amendment in the comprehensive diagnostic workflow management of tumor diseases. It remains a subject of speculation if and to what extend liquids may replace tumor biopsies in the future.
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